Patent Details Novel Antibody-Conjugates for Targeting Tumors Expressing PTK7

Strategic Insights -

Patent Title: Antibody-conjugates for targeting of tumours expressing PTK7, inventor Lianne Lelieveldt, was published online on October 14, 2025, with patent number 12440573. The patent is owned by Synaffix B. V. The invention describes novel antibody-conjugates for targeting tumors expressing PTK7, which has been linked to various cancers including colon, lung, breast, ovarian, and esophageal cancer.

According to the inventors' summary, the antibody-conjugates are highly suitable for targeting PTK7-expressing cells, particularly tumors. The invention covers an antibody-conjugate, a process for preparing it, a method for targeting PTK7-expressing cells, and the use of the conjugate for treating cancer. The claims describe a general structure for the antibody-conjugate, which includes an anti-PTK7 antibody and a conjugated payload.

Key Takeaways:

  • The patent details novel antibody-conjugates for targeting tumors expressing PTK7, which has been linked to various cancers.
  • The invention covers an antibody-conjugate, a process for preparing it, a method for targeting PTK7-expressing cells, and the use of the conjugate for treating cancer.
  • The claims describe a general structure for the antibody-conjugate, which includes an anti-PTK7 antibody and a conjugated payload.
  • The anti-PTK7 antibody is described as being comprised of a light chain and a heavy chain with specific amino acid sequences.
  • The conjugated payload is attached to the anti-PTK7 antibody through a linker, which is attached to the antibody through a glycan chain.
  • The glycan chain can be of varying lengths and compositions, based on the number and types of monosaccharides present.
  • The antibody-conjugate is described as being of the following formula, where AB is the anti-PTK7 antibody, L 6 is the glycan chain, and Z-L-D is the linker payload.
  • The antibody-conjugate is also described as being of a specific formula, where w is 0, j is 0, w' is 0, x is 1, y is 2, Z is a cyclooctyne, and the linker payload is attached to the glycan chain.
  • The antibody-conjugate is described as being of a final formula, where w is 1, Z is a cyclooctyne, and the linker payload is attached to the glycan chain.
  • The patent mentions several specific examples of cytotoxic molecules that can be used as payloads in the antibody-conjugate, including doxorubicin, daunorubicin, nemorubicin, PNU-159,682, SN-38, exatecan, exatecan-S, topotecan, silatecan, cositecan, lurtotecan, gimatecan, belotecan, rubitecan, AMDCPT, G-AMDCPT, calicheamicin, esperamicins, shishijimicins, and namenamicins.
  • The patent also mentions several specific examples of auristatins, which are a class of cytotoxic molecules that can be used as payloads in the antibody-conjugate, including MMAD, MMAE, MMAF, and PF-06380101.

Statistics:

  • The patent was published online on October 14, 2025.
  • The patent is owned by Synaffix B. V.
  • The invention covers an antibody-conjugate, a process for preparing it, a method for targeting PTK7-expressing cells, and the use of the conjugate for treating cancer.
  • The claims describe a general structure for the antibody-conjugate, which includes an anti-PTK7 antibody and a conjugated payload.
  • The anti-PTK7 antibody is described as being comprised of a light chain and a heavy chain with specific amino acid sequences.
  • The conjugated payload is attached to the anti-PTK7 antibody through a linker, which is attached to the antibody through a glycan chain.
  • The glycan chain can be of varying lengths and compositions, based on the number and types of monosaccharides present.
  • The antibody-conjugate is described as being of the following formula, where AB is the anti-PTK7 antibody, L 6 is the glycan chain, and Z-L-D is the linker payload.
  • The antibody-conjugate is also described as being of a specific formula, where w is 0, j is 0, w' is 0, x is 1, y is 2, Z is a cyclooctyne, and the linker payload is attached to the glycan chain.
  • The antibody-conjugate is described as being of a final formula, where w is 1, Z is a cyclooctyne, and the linker payload is attached to the glycan chain.
  • The patent mentions several specific examples of cytotoxic molecules that can be used as payloads in the antibody-conjugate, including doxorubicin, daunorubicin, nemorubicin, PNU-159,682, SN-38, exatecan, exatecan-S, topotecan, silatecan, cositecan, lurtotecan, gimatecan, belotecan, rubitecan, AMDCPT, G-AMDCPT, calicheamicin, esperamicins, shishijimicins, and namenamicins.
  • The patent also mentions several specific examples of auristatins, which are a class of cytotoxic molecules that can be used as payloads in the antibody-conjugate, including MMAD, MMAE, MMAF, and PF-06380101.

Sources:

  • Lelieveldt, Lianne. Antibody-conjugates for targeting of tumours expressing PTK7. U.S. Patent Number 12440573, filed September 20, 2024, and published online on October 14, 2025. Patent URL (for desktop use only): https://ppubs.uspto.gov/pubwebapp/external.html?q=(12440573)&db=USPAT&type=ids